Oncotarget

Research Papers: Gerotarget (Focus on Aging):

Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats

Ekaterina A. Lesovaya, Kirill I. Kirsanov, Elena E. Antoshina, Lubov S. Trukhanova, Tatiana G. Gorkova, Elena V. Shipaeva, Ramiz M. Salimov, Gennady A. Belitsky, Mikhail V. Blagosklonny, Marianna G. Yakubovskaya and Olga B. Chernova _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:9718-9727. https://doi.org/10.18632/oncotarget.3929

Metrics: PDF 1095 views  |   HTML 1687 views  |   ?  


Abstract

Ekaterina A. Lesovaya1,*, Kirill I. Kirsanov1,*, Elena E. Antoshina1, Lubov S. Trukhanova1, Tatiana G. Gorkova1, Elena V. Shipaeva2, Ramiz M. Salimov2, Gennady A. Belitsky1, Mikhail V. Blagosklonny3, Marianna G. Yakubovskaya1,** and Olga B. Chernova4,**

1 Department of Chemical Carcinogenesis, Blokhin Cancer Research Center, Moscow, Russia

2 Tartis-Aging LLC, Moscow, Russia

3 Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, USA

4 Everon Biosciences, Inc., Buffalo, NY, USA

* The first two authors made equal contributions to the study

** The last two authors made equal contributions to the study

Correspondence to:

Marianna Yakubovskaya, email:

Olga B. Chernova, email:

Keywords: gerotarget, aging, benign prostatic hyperplasia, mTOR, rapamycin

Received: December 8, 2014 Accepted: April 15, 2015 Published: April 26, 2015

Abstract

Benign prostatic hyperplasia (BPH) is the most common age-related disease in men. Here we tested the efficacy of Rapatar, a micellar nanoformulation of rapamycin, in two rat models of BPH: testosterone-induced and sulpiride-induced hyperplasia in ventral lobes and lateral/dorsal lobes, respectively. We found that Rapatar prevented hypertrophic and hyperplastic abnormalities and degenerative alterations in both BPH models. Rapatar normalized weight of the lateral lobes in sulpiride-induced BPH, the most relevant animal model of human BPH. Unlike Finasteride, a standard therapy of BPH, Rapatar reduced inflammation caused by sulpiride. No obvious side effects of Rapatar were detected. Our data provide a rationale for clinical trials of Rapatar in patients suffering from BPH.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3929